Life with COPD
transformed
See if the AIRFLOW-4 Clinical Trial is right for you
Over 16 million Americans suffer from chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis.1 COPD can make simple tasks difficult by causing shortness of breath, wheezing, chest tightness, and coughing. These symptoms can get worse over time, making everyday life more challenging. While medications can help manage COPD, they do not always effectively control these symptoms.2,3 If you’re living with COPD and still struggling to control your symptoms, you may qualify for the AIRFLOW-4 Clinical Trial.
AIRFLOW-4 is studying dNerva®
Targeted Lung Denervation.
People with COPD have overactive nerves in their airways, which cause COPD symptoms like shortness of breath, wheezing, COPD flare-ups, and fatigue. dNerva is a one-time non-surgical procedure designed to calm this overactive nerve activity and help improve breathing. Over 500 patients worldwide, including in the United States, have already been treated with dNerva® therapy in clinical trials.
How does it work?
- The treatment is done while you are asleep, via a standard bronchoscope — a thin, flexible tube that goes through your mouth to access your lungs.
- Once in place, targeted energy is delivered to the large airways leading to your right and left lung to disable some of the nerves that cause mucus and airway tightening all through your lungs.
- The entire procedure typically takes about one hour, and in most cases, patients are able to return home the same day.
Why Participate?
COPD treatment is changing.
Medical device research, like this study, is critical to improving outcomes and quality of life for people with COPD. Your participation may help you breathe easier and will help us get closer to finding a solution and bringing new treatments and therapies to more people with COPD.
If you’re living with COPD and continue to struggle with symptoms despite medication, you may be eligible for the AIRFLOW-4 Clinical Trial.
By joining the study, eligible participants will receive:
- Comprehensive evaluations of your COPD by a local specialist
- All study-related tests, the procedure and visits at no cost
- Regular monitoring of your symptoms and overall health over a 2-year period
- Reimbursement for travel expenses, and potentially your time for study visits
SEE IF YOU QUALIFY
See if you qualify:
To see if you might qualify for the AIRFLOW-4 Clinical Trial, and to get connected with your local study center to learn more, please take the questionnaire below.
Safety Information
As with any medical procedure, there are potential risks. Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.
dNerva® Lung Denervation System is an investigational device and is not yet approved by the FDA for commercial use in the United States.
All content on this website has been reviewed and approved by Institutional Review Boards (IRBs) at both the site and central levels.
1. National Heart, Lung, and Blood Institute https://www.nhlbi.nih.gov/health-topics/education-and-awareness/COPD-national-action-plan
2. Lipson, IMPACT Study, NEJM 2018
3. Rabe, ETHOS Study, NEJM 2020